The European Society for Medical Oncology (ESMO) clinical practice guidelines for the management of cancer pain in adult patients recommend opioids as the mainstay of treatment for moderate to severe cancer pain, including pain from bone metastases. For patients with severe pain requiring urgent relief, the guideline recommends parenteral opioid titration (subcutaneous or intravenous) rather than oral therapy. Intravenous opioid administration is specifically recommended when rapid pain control is needed and rescue doses should also be prescribed for breakthrough pain. [1]
For patients with chronic kidney disease stage 4 or 5 or those receiving dialysis, the guideline notes that opioid dose adjustment is generally required due to accumulation of active metabolites, which may cause opioid toxicity including confusion, drowsiness, and hallucinations. It recommends using smaller doses and longer dosing intervals in mild renal dysfunction and identifies fentanyl and buprenorphine (transdermal or intravenous) as the safest opioids for patients with severe renal dysfunction or dialysis (Level III, Grade B). Oral methadone is also described as an effective alternative opioid, particularly when accumulation of active opioid metabolites is suspected, although it should be prescribed by clinicians experienced in its use. [1]
Regarding bone pain due to bone metastases, the guideline states that treatment should include analgesic medications, with external beam radiotherapy, radioisotopes, and targeted therapies playing important roles in conjunction with analgesics. The guideline recommends offering external beam radiotherapy to all patients with painful bone metastases (Level I, Grade A). Although bisphosphonates may be considered as part of the therapeutic regimen for patients with bone metastases, the guideline notes that evidence supporting their analgesic efficacy for established bone pain is weak, particularly in the short term, and they should be used in conjunction with analgesics. Additionally, a systematic review cited by the guideline found that denosumab and bisphosphonates primarily delay the onset of pain rather than provide analgesia for established pain. Overall, general cancer pain management emphasizes opioid analgesia, with bone-directed therapies used in conjunction with analgesics for the management of pain due to bone metastases. [1]
A 2022 guideline developed by the American Society of Clinical Oncology (ASCO) systematically reviewed the use of opioids for managing pain in adults with cancer or undergoing cancer treatment. Although the guideline addresses cancer-related pain broadly and is not specific to metastatic bone pain, it includes recommendations for opioid selection and monitoring in patients with renal impairment. For patients with renal impairment, the guideline recommends considering rotation to methadone, when not contraindicated, because it is primarily excreted fecally (informal consensus; strong recommendation). Fentanyl, oxycodone, and hydromorphone may also be used, but require careful dose titration and frequent monitoring because of the potential for accumulation of the parent drug or active metabolites. In contrast, morphine, meperidine, codeine, and tramadol should generally be avoided unless no suitable alternatives are available (informal consensus; strong recommendation). The guideline also recommends more frequent clinical observation and opioid dose adjustment in patients with renal impairment receiving opioids. These recommendations were based largely on limited evidence, as a 2017 systematic review including 18 nonrandomized studies found no clear evidence to identify a preferred opioid for patients with cancer pain and renal impairment, and the panel therefore relied primarily on expert consensus. The guideline further notes that methadone has potential advantages in this population because of its relative safety in renal impairment, but given its complex pharmacokinetic and pharmacodynamic properties, it should only be initiated or used for opioid rotation by experienced clinicians. [2]
A 2026 National Comprehensive Cancer Network (NCCN) guideline for Adult Cancer Pain discusses the management of cancer-related pain, including pain associated with bone metastases, but is not specific to acute pain or to patients with end-stage renal disease. The guideline notes that NSAIDs, acetaminophen, or corticosteroids may improve bone pain control when used in combination with opioid analgesics, and that topical diclofenac (gel, solution, or patch) may provide relief for pain due to bone metastases with minimal systemic effects. For patients with localized painful bone metastases or impending skeletal complications, radiation therapy and surgical intervention may be used to relieve pain, provide stabilization, and prevent fracture or spinal cord compression. Consultation with pain or palliative care specialists and consideration of interventional approaches, such as vertebral augmentation or image-guided ablation, are also recommended in selected patients. [3]
According to the World Health Organization (WHO) guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents, initiation of cancer pain management should include NSAIDs, paracetamol, and opioids, either alone or in combination based on clinical assessment and pain severity, to achieve rapid, effective, and safe pain control (strong recommendation; low-quality evidence). For moderate or severe pain, mild analgesics should not be used alone, and patients may be started on a combination of paracetamol and/or NSAIDs with an opioid, such as oral morphine. The guideline also recommends adjuvant corticosteroids when indicated for cancer pain, including metastatic bone pain (strong recommendation; moderate-quality evidence). [4], [5]
For metastatic bone pain, the WHO guideline recommends considering radiotherapy for patients whose pain is difficult to control with pharmacologic therapy and states that these patients should be evaluated for external beam radiotherapy or radioisotope treatment. When radiotherapy is indicated and available, the WHO recommends single-dose fractionated radiotherapy (strong recommendation; high-quality evidence). Similarly, the American Society for Radiation Oncology (ASTRO) recommends external beam radiotherapy for patients with symptomatic bone metastases to reduce pain and for symptomatic spinal metastases, including those causing spinal cord or cauda equina compression, to improve ambulatory status, sphincter function, and pain following evaluation for spinal stability and the need for surgery. The WHO also recommends bisphosphonates to prevent and treat bone pain in patients with bone metastases (strong recommendation; moderate-quality evidence), while advising clinicians to consider their variable adverse renal effects before prescribing. The WHO makes no recommendation for or against radioisotopes or monoclonal antibodies due to insufficient or limited evidence. [4], [5]
A 2011 systematic review conducted as part of the European Palliative Care Research Collaborative (EPCRC) opioid guidelines project, evaluated the evidence for the safe and effective use of opioids for cancer-related pain in patients with renal impairment. Fifteen clinical studies (8 prospective and 7 retrospective) were identified, and no randomized controlled trials met the inclusion criteria. The authors concluded that the overall evidence was very low quality, with substantial risk of study and publication bias, and was insufficient to formulate clinical guidelines based on direct evidence alone. Consequently, recommendations were based on pharmacokinetic data, extrapolation from non-cancer pain studies, and clinical experience. Fentanyl, alfentanil, and methadone were identified as the opioids least likely to cause harm when used appropriately in patients with renal impairment, whereas morphine was associated with an increased risk of toxicity due to accumulation of active metabolites. The authors also emphasized that renal impairment should not delay opioid use for cancer pain when indicated, but recommended close monitoring for toxicity and preferential use of opioids without clinically significant active metabolites. Notably, the review did not specifically evaluate or report outcomes for patients with metastatic bone pain. [6]
A 2008 article on management of bone metastases states that steroids, specifically dexamethasone, are preferred for short-term relief from bone pain due to their ability to be administered parenterally and their quick action, typically within 24 to 48 hours. In palliative pain management, a common dosing range is 4 to 16 mg of dexamethasone. Given its long half-life, administering dexamethasone in the morning minimizes the risk of insomnia. For rapid pain control, it is advisable to start with the highest dose and adjust as needed based on effectiveness. Once pain is managed, the dosage should be gradually reduced to the lowest effective amount. In older adults, dosages should be significantly decreased due to the risk of side effects like psychosis. The article did not address corticosteroid use specifically in patients with end-stage renal disease. [7]